Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Early introduction of oral paricalcitol in renal transplant recipients

ABSTRACT: In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft. A single centre, prospective, randomized, open label trial investigating the additional effect of paricalcitol 2ug/day to standard care was performed. Participants were included 8 weeks after engraftment irrespective of PTH-level and followed for 44 weeks. Microarray analyses were performed in kidney biopsies at study end for the investigation of potential effects on gene expression profile. This dataset is part of the TransQST collection.

ORGANISM(S): Homo sapiens

SUBMITTER: Hege Pihlstrøm 

PROVIDER: E-GEOD-83486 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.

Pihlstrøm Hege Kampen HK   Gatti Franscesca F   Hammarström Clara C   Eide Ivar Anders IA   Kasprzycka Monika M   Wang Junbai J   Haraldsen Guttorm G   Svensson My Hanna Sofia MHS   Midtvedt Karsten K   Mjøen Geir G   Dahle Dag Olav DO   Hartmann Anders A   Holdaas Hallvard H  

Transplant international : official journal of the European Society for Organ Transplantation 20170602 8

In stable renal transplant recipients with hyperparathyroidism, previous studies have indicated that vitamin D agonist treatment might have anti-proteinuric effects. Animal studies indicate possible anti-fibrotic and anti-inflammatory effects. Early introduction of paricalcitol in de novo renal transplant recipients might reduce proteinuria and prevent progressive allograft fibrosis. We performed a single-center, prospective, randomized, open-label trial investigating effects of paricalcitol 2 μ  ...[more]

Similar Datasets

Transcriptomics Early introduction of oral paricalcitol in renal transplant recipients.
2017-09-01 | GSE83486 | GEO
Transcriptomics Monocytic HLA-DR density in renal transplant recipients
2022-06-02 | GSE205122 | GEO
Genomics Kidney transplant recipients
| PRJNA1054489 | ENA
Genomics Monocytic HLA-DR density in renal transplant recipients
| PRJNA843961 | ENA
Genomics Biomarkers in Transplant Recipients
| PRJNA290675 | ENA
Genomics The Gut Microbiome of renal transplant recipients – Cross-sectional
| EGAS00001006257 | EGA
Genomics The Gut Microbiome of liver transplant recipients – Cross-sectional + Longitudinal (renal and liver)
| EGAS00001006258 | EGA
Transcriptomics Transcriptional Responses Define Dysregulated Immune Activation in Hepatitis C (HCV)-Naïve Recipients of HCV-Infected Donor Kidneys
2023-02-08 | GSE213705 | GEO
Transcriptomics MOLECULAR CHARACTERIZATION OF LIVER ALLOGRAFTS FROM OPERATIONALLY TOLERANT TRANSPLANT RECIPIENTS
2012-01-09 | E-GEOD-26627 | biostudies-arrayexpress
Transcriptomics Single-cell transcriptomics of peripheral blood reveals a novel B-cell subset in renal allograft recipients with accommodation
2021-05-25 | GSE175429 | GEO